Proteolytic cleavage during chemotherapy-induced apoptosis |
| |
| Affiliation: | 1. Univ. Grenoble Alpes, Inserm, U1216, CNRS, Grenoble Institut Neurosciences, 38000 Grenoble, France;2. Institute of Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;3. DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Hamburg, Germany;1. Analytical Biosciences and Metabolomics, Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Einsteinweg 55, 2333, CC Leiden, the Netherlands;2. Technological University Dublin, Tallaght Campus, Department of Applied Science, Dublin 24, Ireland;3. University of Amsterdam, van ’t Hoff Institute for Molecular Science (HIMS), Amsterdam, the Netherlands;1. Plant Cytogenomics Group, CEITEC – Central European Institute of Technology, Masaryk University, Kamenice 5, Brno CZ-62500, Czech Republic;2. Biosystematics Group, Wageningen University (WU), Droevendaalsesteeg 1, Wageningen 6708 PB, The Netherlands |
| |
| Abstract: | Treatment with anticancer drugs sets into motion a morphologically and biochemically distinct type of cell death called apoptosis. Recent genetic and biochemical studies have suggested that proteases play a prominent role in the active phase of apoptotic cell death. Ongoing studies are aimed at identifying the proteases involved, the substrates that are cleaved, and the means by which the proteolytic process is regulated in nonapoptotic and apoptotic cells. The possibility that these findings will suggest new approaches to treating cancer and other diseases is discussed. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
